Related references
Note: Only part of the references are listed.Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma
John D. Hainsworth et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Cancer-related fatigue-mechanisms, risk factors, and treatments
Julienne E. Bower
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Krishnansu S. Tewari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
Catherine Beauchemin et al.
ONCOTARGETS AND THERAPY (2014)
Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials
Qing Ye et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2013)
AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
Luca Gianni et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
David Cameron et al.
LANCET ONCOLOGY (2013)
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
David Cunningham et al.
LANCET ONCOLOGY (2013)
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
Jaafar Bennouna et al.
LANCET ONCOLOGY (2013)
The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review
Limor Amit et al.
PLOS ONE (2013)
Can trial quality be reliably assessed from published reports of cancer trials: evaluation of risk of bias assessments in systematic reviews
Claire L. Vale et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma
Kevin B. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
William Kevin Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma
Hedy L. Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
Aimery de Gramont et al.
LANCET ONCOLOGY (2012)
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer
Seiji Niho et al.
LUNG CANCER (2012)
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
Harry D. Bear et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Effect of Angiogenesis Inhibitor Bevacizumab on Survival in Patients with Cancer: A Meta-Analysis of the Published Literature
Yuan Su et al.
PLOS ONE (2012)
Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
Beth Sherrill et al.
ONCOTARGETS AND THERAPY (2012)
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
Zhong-Zhen Guan et al.
Chinese Journal of Cancer (2012)
Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis
Amna Sher et al.
ACTA ONCOLOGICA (2011)
Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive Stage Small-Cell Lung Cancer Findings on the Basis of North Central Cancer Treatment Group Trials
Nathan R. Foster et al.
CANCER (2011)
Haematologic toxicities associated with the addition of bevacizumab in cancer patients
Fabio A. B. Schutz et al.
EUROPEAN JOURNAL OF CANCER (2011)
Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials
Xiao Feng Hang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Chemotherapy With or Without Bevacizumab in Patients With Resected Hepatic Metastases From Colorectal Cancer
Nancy E. Kemeny et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Adam M. Brufsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer
Nicholas J. Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
Roy S. Herbst et al.
LANCET (2011)
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study
Miguel Martin et al.
LANCET ONCOLOGY (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials
Vishal Ranpura et al.
ACTA ONCOLOGICA (2010)
Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A. Meta-Analysis
Vishal Ranpura et al.
AMERICAN JOURNAL OF HYPERTENSION (2010)
Effectiveness and Safety of Bevacizumab for Unresectable Non-Small-Cell Lung Cancer A Meta-Analysis
Kun Yang et al.
CLINICAL DRUG INVESTIGATION (2010)
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy Lee Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
David W. Miles et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bevacizumab Increases Risk for Severe Proteinuria in Cancer Patients
Shenhong Wu et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Safety of Bevacizumab in Patients with Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials
Sabine Geiger-Gritsch et al.
ONCOLOGIST (2010)
Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Study
G. P. Stathopoulos et al.
ONCOLOGY (2010)
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
David Moher et al.
INTERNATIONAL JOURNAL OF SURGERY (2010)
International randomised phase III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) in first line treatment of metastatic colorectal cancer (mCRC): final results of the AGITG MAX trial
N. Tebbutt et al.
EJC SUPPLEMENTS (2009)
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
Kristine R. Broglio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
Sanjaykumar Hapani et al.
LANCET ONCOLOGY (2009)
Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
J. -J. Mourad et al.
ANNALS OF ONCOLOGY (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 Randomized controlled trials of first-line chemotherapy
Patricia A. Tang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Bruce J. Giantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis
Xiaolei Zhu et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
KD Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
DH Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
JC Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
F Kabbinavar et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)